Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 482 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inflammatory Tissue Disorder Clear all
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

NCT02623972
View directory record Official record
Conditions
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions
Eribulin, Adriamycin, Cyclophosphamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 22, 2026, 5:13 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Psoriatic Arthritis Study of Izokibep

NCT05623345
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Izokibep, Placebo to izokibep
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
40
States / cities
Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 22, 2026, 5:13 AM EDT
Not yet recruiting Phase 1 Interventional

A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases

NCT07873931
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Lupus Nephritis
Interventions
BMS-986553
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
11
States / cities
Newport Beach, California • Worcester, Massachusetts • Ann Arbor, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

NCT00499122
View directory record Official record
Conditions
Breast Cancer
Interventions
Cyclophosphamide, Docetaxel, Doxorubicin, NOV 002
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Miami, Florida • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 22, 2026, 5:13 AM EDT
Completed No phase listed Observational

Characterization of Multisystem Inflammatory Syndrome in Children (MIS-C) and Its Relationship to Kawasaki Disease

NCT04538495
View directory record Official record
Conditions
Kawasaki Disease, Inflammation
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
1 Month and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 22, 2026, 5:13 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Use of Topical NSAID to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions.

NCT03509675
View directory record Official record
Conditions
Oral Lichen Planus, Oral Lichenoid Mucositis, Oral Lichenoid Reaction
Interventions
Ibuprofen suspension 5mg/100ml, Placebos
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 22, 2026, 5:13 AM EDT
Completed Phase 2Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

NCT05523167
View directory record Official record
Conditions
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions
EFG PH20 SC, PBO
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 22, 2026, 5:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions: The Corrona CERTAIN Sub-study

NCT01625650
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
2,795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 22, 2026, 5:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Efficacy of Bakuchiol in Treating PIH

NCT06833996
View directory record Official record
Conditions
Post Inflammatory Hyperpigmentation
Interventions
Bakuchiol, Vehicle
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 22, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602
View directory record Official record
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 22, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Open Label Pilot Study of Apremilast in Treatment of Rosacea

NCT01045551
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Interventions
Apremilast
Drug
Lead sponsor
Julian M. Mackay-Wiggan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 22, 2026, 5:13 AM EDT
Withdrawn Not applicable Interventional

Excimer Laser, Serum Markers & Psoriasis

NCT02165657
View directory record Official record
Conditions
Psoriasis
Interventions
Excimer laser treatment
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Concord, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 22, 2026, 5:13 AM EDT
Completed Phase 1 Interventional

Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions

NCT00001764
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 5:13 AM EDT
Recruiting No phase listed Observational

Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study

NCT06339177
View directory record Official record
Conditions
Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, Hyperinflammatory Syndromes
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 22, 2026, 5:13 AM EDT
Terminated Phase 3 Interventional Results available

Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease

NCT00770601
View directory record Official record
Conditions
NOMID, CINCA Syndrome
Interventions
Canakinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 25 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 22, 2026, 5:13 AM EDT
Active, not recruiting Phase 2 Interventional

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

NCT02876107
View directory record Official record
Conditions
Breast Carcinoma, Breast Lump, Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Invasive Breast Carcinoma, Peau d'Orange, Progesterone Receptor Negative, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Panitumumab
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 5:13 AM EDT
Completed Phase 1 Interventional

Effects of Endotoxin in Normal Human Volunteers

NCT00001303
View directory record Official record
Conditions
Healthy, Lung Disease, Sepsis, Septic Shock
Interventions
Reference Endotoxin, Inhaled Nitric Oxide
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 45 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 22, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01212770
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 22, 2026, 5:13 AM EDT
Completed No phase listed Observational

Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients

NCT01213641
View directory record Official record
Conditions
Cryopyrin-associated Periodic Syndromes (CAPS), Familial Cold Autoinflam Syn (FCAS), Muckle-wells Syn (MWS), Neonatal Onset Multisystem Inflam Disease (NOMID)
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Little Rock, Arizona • Columbus, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 22, 2026, 5:13 AM EDT
Not yet recruiting No phase listed Observational

TDAP in Burn Patients (Group 2)

NCT07223684
View directory record Official record
Conditions
Sepsis, Burn Injury, Wound Healing, Critical Illness, Multiple Organ Dysfunction Syndrome
Interventions
Observational Cohort (No Intervention)
Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 22, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

NCT04018599
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 22, 2026, 5:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Serum Protein Patterns in Participants With Mycosis Fungoides/Cutaneous T-Cell Lymphoma, Psoriasis, or Normal Skin

NCT00066664
View directory record Official record
Conditions
Lymphoma
Interventions
proteomic profiling
Genetic
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 85 Years
Enrollment
423 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
4
States / cities
Stanford, California • Baltimore, Maryland • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 22, 2026, 5:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers

NCT00001164
View directory record Official record
Conditions
Healthy, Muscular Dystrophy, Retinal Degeneration, Skin Diseases, Virus Diseases
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
1978 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Oct 22, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dexamethasone Solution and Dexamethasone in Mucolox™

NCT04540133
View directory record Official record
Conditions
Oral Lichen Planus, Mucous Membrane Pemphigoid, Pemphigus Vulgaris, Chronic Graft-versus-host-disease
Interventions
dexamethasone 0.5mg/5ml solution, dexamethasone 0.5mg/5ml solution in Mucolox™
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 22, 2026, 5:13 AM EDT